In addition, the delivery of CAPE to MM cells was significantly (p < 0.0001) improved when RGD-IONP were used as carriers, evidenced by the further reduced populations of non-apoptotic RPMI8226 cells after a 24-h treatment with RGD-IONP/CAPE (58% ± 0.5%) versus those of non-targeted IONP/CAPE (65% ± 0.5%) and CAPE alone (70% ± 0.3%) at the CAPE concentration of 30 μM (Figure 5B). Here, SMC2 is linked to Miyoshi myopathy.